
Adaptimmune appoints PwC head to board
pharmafile | March 12, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Lawrence Alleva, adaptimune, pwC
Clinical-stage biotech firm Adaptimmune has appointed Lawrence Alleva as a non-executive director who is also to serve as chairman of its audit committee.
Alleva is a former partner with PricewaterhouseCoopers LLP (PwC) where he served for 39 years until his retirement in June 2010, that comprised 28 years’ service as a partner.
He worked with numerous pharma and biotech companies as clients and served PwC in a variety of leadership roles, most recently as the US ethics and compliance leader for its Assurance Practice from 2006 until his retirement.
Alleva currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for privately-held Mirna Therapeutics – whilst also chairing the audit committee for those companies.
“I am delighted that such a high caliber individual as Larry Alleva has agreed to join our board of directors,” says Dr Jonathan Knowles, chairman of Adaptimmune. “His substantial corporate finance and accounting expertise, combined with his extensive experience of supporting growing biotech firms, brings significant added value to the company, and complements the skills and experience of our other board members.”
Alleva adds: “I am very pleased to be joining Adaptimmune at this interesting time, and I look forward to working closely with the team as we aim to build the company up with the expansion of its UK and US operations.”
Related Content

Nigerian agency strongly contests that 70% of drugs are fake
Nigeria’s drug regulatory body has fiercely countered claims made by Chief Economist of PwC in …

AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide …

Consumers want more from wearables market
The interest in mobile health (mHealth) wearables is gaining traction, but consumers want more affordable …






